DYTN

Across TCGA pan-cancer cohorts, DYTN Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DYTN data layer compared with 22 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher DYTN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DYTN expression acts as an unfavorable survival marker.

BRCA, ACC, and KIRP are the cancer types where DYTN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.734	0.964	<.001	29	view →
ACC	OS	Median	All	0.114	0.892	<.001	24	view →
KIRP	OS	Median	All	0.272	0.885	<.001	12	view →
COAD	OS	Median	All	0.360	0.812	<.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	IV	0.589	0.754	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DYTN–BRCA (OS)

Open the BRCA breakdown →